GCP
TRDA icon

GSA Capital Partners’s Entrada Therapeutics TRDA Stock Holding History

GSA Capital Partners’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$648K Buy
+88,005
New +$844K 0.04% 831
2025
Q4 		– Sell
-55,960
Closed -$325K – 2090
2025
Q3 		$325K Buy
+55,960
New +$327K 0.03% 1152
2024
Q4 		– Sell
-36,577
Closed -$585K – 2036
2024
Q3 		$585K Buy
36,577
+15,284
+72% +$241K 0.04% 818
2024
Q2 		$303K Buy
+21,293
New +$303K 0.02% 1278

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCG Crossover Management
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

GSA Capital Partners's TRDA Position: Q2 2026 in Review

GSA Capital Partners opened a new position in Entrada Therapeutics (TRDA) in Q2 2026: 88,005 shares worth $648K. The stake represents 0.04% of the portfolio and ranks #831 among its holdings. This is a return to the name: GSA Capital Partners previously reported a position in TRDA as recently as Q3 2025.

GSA Capital Partners first reported a position in TRDA in Q2 2024 and has held it in 4 quarters since. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • GSA Capital Partners held 88,005 shares of Entrada Therapeutics worth $648K as of Q2 2026.
  • Entrada Therapeutics was a new GSA Capital Partners position in Q2 2026.
  • Entrada Therapeutics made up 0.04% of GSA Capital Partners's portfolio in Q2 2026, its #831 holding.
  • GSA Capital Partners first reported a position in Entrada Therapeutics in Q2 2024 and has held it in 4 quarters since.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on GSA Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.